Related Experiment Video
Updated: Feb 8, 2026

Three-dimensional Alginate-bead Culture of Human Pituitary Adenoma Cells
Published on: February 18, 2016
Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
Luis V Syro1, Fabio Rotondo2, Mauricio Camargo3
1Department of Neurosurgery, Hospital Pablo Tobon Uribe and Clinica Medellin, Medellin, Colombia.
Abstract:
Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy.
More Related Videos
Related Concept Videos
Hypothalamic-Pituitary Axis
Ethical Issues
Ethical Concerns in Healthcare:
Hormones of the Pituitary Gland
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
The Pituitary Gland
Understanding the Self
Understanding Self-Concept

